Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oseni

- PMLiVE

New type of inhibitor drug could prevent microvascular diabetic complications

The drug could prevent conditions including diabetic eye and kidney disease in diabetes

- PMLiVE

Takeda gains rights to Protagonist’s blood disorder asset in deal worth over $300m

Rusfertide is currently being evaluated in a phase 3 clinical trial to treat polycythaemia vera

- PMLiVE

Takeda’s HyQvia receives EC approval for rare neuromuscular disorder CIDP

HyQvia can now be used as a maintenance therapy for patients of all ages with CIDP

- PMLiVE

Takeda’s HyQvia granted FDA approval to treat rare neuromuscular disorder CIDP

Approximately five to seven people per 100,000 in the US are affected by the disorder

- PMLiVE

Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn

The company will gain access to a portfolio of incretin-based therapies for diabetes and obesity

- PMLiVE

Eli Lilly to expand injectable manufacturing capacity with new $2.5bn facility in Germany

The site is expected to be operational in 2027 and will employ up to 1,000 highly skilled workers

- PMLiVE

Takeda’s enzyme replacement therapy approved by FDA for rare blood clotting disorder

The ultra-rare inherited disease is estimated to affect fewer than 1,000 people in the US

- PMLiVE

Takeda’s Fruzaqla receives FDA approval for metastatic colorectal cancer

More than 150,000 new cases of colorectal cancer will be diagnosed in the US in 2023

- PMLiVE

Takeda announces EC approval for Adcetris combination in Hodgkin lymphoma

The ADC has been approved alongside doxorubicin, vinblastine and dacarbazine

- PMLiVE

Takeda announces CHMP recommendation for Adcetris in Hodgkin lymphoma

The ADC has been recommended with doxorubicin, vinblastine and dacarbazine

- PMLiVE

Takeda announces positive phase 2b results for TAK-279 in psoriatic arthritis

Approximately 10 million people worldwide are affected by the inflammatory disease

- PMLiVE

Novo Nordisk enters new research alliance for diabetes and cardiometabolic diseases

The collaboration will focus on advancing three programmes across the next three years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links